These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 15653665)
1. The promise of immuno-PET in radioimmunotherapy. Verel I; Visser GW; van Dongen GA J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665 [TBL] [Abstract][Full Text] [Related]
2. Antibody-based cancer therapies: back to "polyclonals"? Paganelli G; De Santis R Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1453-5. PubMed ID: 15258701 [No Abstract] [Full Text] [Related]
3. Current status of therapy of solid tumors: brain tumor therapy. Zalutsky MR J Nucl Med; 2005 Jan; 46 Suppl 1():151S-6S. PubMed ID: 15653663 [TBL] [Abstract][Full Text] [Related]
4. The promise of targeted {alpha}-particle therapy. Mulford DA; Scheinberg DA; Jurcic JG J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670 [TBL] [Abstract][Full Text] [Related]
5. Radioimmunodetection and therapy of breast cancer. DeNardo SJ Semin Nucl Med; 2005 Apr; 35(2):143-51. PubMed ID: 15765377 [TBL] [Abstract][Full Text] [Related]
6. Current status of therapy of solid tumors. Jhanwar YS; Divgi C J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662 [TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. Reilly RM J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623 [No Abstract] [Full Text] [Related]
9. Immuno-PET: a navigator in monoclonal antibody development and applications. van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach. Stipsanelli E; Valsamaki P Hell J Nucl Med; 2005; 8(2):103-8. PubMed ID: 16142251 [TBL] [Abstract][Full Text] [Related]
11. A pragmatic perspective on molecular targeted radionuclide therapy. Larson SM; Krenning EP J Nucl Med; 2005 Jan; 46 Suppl 1():1S-3S. PubMed ID: 15653645 [No Abstract] [Full Text] [Related]
12. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. Sharkey RM; Goldenberg DM J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660 [TBL] [Abstract][Full Text] [Related]
13. The direct route may not be the best way to home. Sharkey RM J Nucl Med; 2005 Mar; 46(3):391-4. PubMed ID: 15750148 [No Abstract] [Full Text] [Related]
14. Advances in cancer therapy with radiolabeled monoclonal antibodies. Goldenberg DM; Sharkey RM Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):248-64. PubMed ID: 17043623 [TBL] [Abstract][Full Text] [Related]
15. Letter from the editors. Freeman LM; Blaufox MD Semin Nucl Med; 2005 Apr; 35(2):83. PubMed ID: 15765371 [No Abstract] [Full Text] [Related]
16. Future direction of renal positron emission tomography. Szabo Z; Xia J; Mathews WB; Brown PR Semin Nucl Med; 2006 Jan; 36(1):36-50. PubMed ID: 16356795 [TBL] [Abstract][Full Text] [Related]
17. Immuno-positron emission tomography: shedding light on clinical antibody therapy. van Dongen GA; Vosjan MJ Cancer Biother Radiopharm; 2010 Aug; 25(4):375-85. PubMed ID: 20707716 [TBL] [Abstract][Full Text] [Related]
18. The role of FDG PET in the management of lymphoma: what is the evidence base? Kirby AM; Mikhaeel NG Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883 [TBL] [Abstract][Full Text] [Related]